AHS Cancer Control Alberta

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Extensive Stage Small Cel Lung Cancer

First Posted Date: 2008-03-26

Last Posted Date: 2016-02-26

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 30

Registration Number: NCT00643396

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Quantifying Lung Tumor Movement Under Deep Inspiration Breath Holds

Completed

Conditions: Lung Cancer

Interventions: Other: CT scan of the chest under deep inspiration breath hold

First Posted Date: 2008-03-26

Last Posted Date: 2016-02-17

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 8

Registration Number: NCT00643370

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial

Phase 2

Completed

Conditions: Urothelial Cancer
Bladder Cancer
Adult

Interventions: Drug: SU011248
Drug: Placebo

First Posted Date: 2007-12-21

Last Posted Date: 2018-08-22

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 64

Registration Number: NCT00578526

Locations: 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 2 locations

A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2007-12-03

Last Posted Date: 2016-03-11

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 23

Registration Number: NCT00566410

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation Therapy

Terminated

Conditions: Breast and Skin Motion
Genetic Markers
Cardiac Toxicity

First Posted Date: 2007-11-26

Last Posted Date: 2016-02-24

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 16

Registration Number: NCT00563407

Locations: 🇨🇦
Alberta Cancer Board, Edmonton, Alberta, Canada

FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma

Not Applicable

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: R-CHOP
Procedure: Autologous Blood Stem Transplantation

First Posted Date: 2007-09-17

Last Posted Date: 2019-01-22

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 69

Registration Number: NCT00530179

Locations: 🇨🇦
Ottawa General Hospital, Ottawa, Ontario, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Saskatchewan Cancer Agency, Regina, Saskatchewan, Canada

PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy

Completed

Conditions: Squamous Cell Cancer

Interventions: Other: PET-CT

First Posted Date: 2007-09-17

Last Posted Date: 2019-10-21

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 20

Registration Number: NCT00530283

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

Blood Test to Measure DNA Damage in Blood

Terminated

Conditions: Prostate Cancer

First Posted Date: 2007-08-31

Last Posted Date: 2016-02-26

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 40

Registration Number: NCT00523471

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial

Not Applicable

Completed

Conditions: Breast Neoplasms

Interventions: Behavioral: Aerobic exercise intervention

First Posted Date: 2007-08-29

Last Posted Date: 2015-01-15

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 320

Registration Number: NCT00522262

Locations: 🇨🇦
Alberta Cancer Board, Calgary, Alberta, Canada
🇨🇦
University of Alberta, Edmonton, Alberta, Canada

A Pilot Study to Evaluate the Feasibility of Combining Submandibular Salivary Gland Tx & IMRT Tomo to Reduce Xerostomia

Not Applicable

Conditions: Head and Neck Cancer

First Posted Date: 2007-07-06

Last Posted Date: 2016-03-16

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 46

Registration Number: NCT00497406

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy